Tags

Type your tag names separated by a space and hit enter

Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.
Int J Neuropsychopharmacol. 2012 Oct; 15(9):1251-64.IJ

Abstract

Although a wealth of preclinical evidence indicates an interplay between the μ-opioid (MOR) and cannabinoid 1 receptor (CB1R) systems, the precise nature of the cross modulation in humans is unclear. The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Δ9-tetrahydrocannabinol (THC), in healthy human subjects. Healthy human subjects, screened carefully for any medical or psychiatric illness, were administered either placebo or active naltrexone (25 mg) orally on each test day, followed 45 min later by placebo and 165 min later by active i.v. THC (0.025 mg/kg) in a randomized, fixed-order, double-blind manner. Subjective, behavioural and cognitive effects were assessed before and at several points after each drug administration. THC produced expected effects, including euphoria, anxiety, transient perceptual alterations, transient psychotomimetic effects and cognitive impairments. However, naltrexone did not produce any effects alone, nor did it attenuate any of THC's effects. Thus, in healthy human subjects who use cannabis intermittently, MOR antagonism does not modulate the common acute subjective, behavioural and cognitive effects of THC.

Authors+Show Affiliations

Yale University, School of Medicine, Department of Psychiatry, New Haven, CT, USA. mohini.ranganathan@yale.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22243563

Citation

Ranganathan, Mohini, et al. "Naltrexone Does Not Attenuate the Effects of Intravenous Δ9-tetrahydrocannabinol in Healthy Humans." The International Journal of Neuropsychopharmacology, vol. 15, no. 9, 2012, pp. 1251-64.
Ranganathan M, Carbuto M, Braley G, et al. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol. 2012;15(9):1251-64.
Ranganathan, M., Carbuto, M., Braley, G., Elander, J., Perry, E., Pittman, B., Radhakrishnan, R., Sewell, R. A., & D'Souza, D. C. (2012). Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal of Neuropsychopharmacology, 15(9), 1251-64. https://doi.org/10.1017/S1461145711001830
Ranganathan M, et al. Naltrexone Does Not Attenuate the Effects of Intravenous Δ9-tetrahydrocannabinol in Healthy Humans. Int J Neuropsychopharmacol. 2012;15(9):1251-64. PubMed PMID: 22243563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. AU - Ranganathan,Mohini, AU - Carbuto,Michelle, AU - Braley,Gabriel, AU - Elander,Jaqueline, AU - Perry,Edward, AU - Pittman,Brian, AU - Radhakrishnan,Rajiv, AU - Sewell,Richard A, AU - D'Souza,Deepak C, Y1 - 2012/01/16/ PY - 2012/1/17/entrez PY - 2012/1/17/pubmed PY - 2013/1/18/medline SP - 1251 EP - 64 JF - The international journal of neuropsychopharmacology JO - Int. J. Neuropsychopharmacol. VL - 15 IS - 9 N2 - Although a wealth of preclinical evidence indicates an interplay between the μ-opioid (MOR) and cannabinoid 1 receptor (CB1R) systems, the precise nature of the cross modulation in humans is unclear. The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Δ9-tetrahydrocannabinol (THC), in healthy human subjects. Healthy human subjects, screened carefully for any medical or psychiatric illness, were administered either placebo or active naltrexone (25 mg) orally on each test day, followed 45 min later by placebo and 165 min later by active i.v. THC (0.025 mg/kg) in a randomized, fixed-order, double-blind manner. Subjective, behavioural and cognitive effects were assessed before and at several points after each drug administration. THC produced expected effects, including euphoria, anxiety, transient perceptual alterations, transient psychotomimetic effects and cognitive impairments. However, naltrexone did not produce any effects alone, nor did it attenuate any of THC's effects. Thus, in healthy human subjects who use cannabis intermittently, MOR antagonism does not modulate the common acute subjective, behavioural and cognitive effects of THC. SN - 1469-5111 UR - https://www.unboundmedicine.com/medline/citation/22243563/Naltrexone_does_not_attenuate_the_effects_of_intravenous_Δ9_tetrahydrocannabinol_in_healthy_humans_ L2 - https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145711001830 DB - PRIME DP - Unbound Medicine ER -